SLC-0111 is a first-in-class small molecule which selectively inhibits Carbonic Anhydrase IX (CAIX) (Company Web Page, Welichem Biotech, MAR 30, 2018, View Source [SID1234525068]). It has been in phase I clinical trials in multi-centers in Canada to establish a maximum tolerable dose and pharmacokinetics in cancer patients since October 2014. The completion of the study is anticipated by Q3 2016. SLC has entered into a partnership to develop this compound with Welichem Biotech Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!